Author | Caroline Robert, MD, PhD

Articles

BRAF, MEK Inhibition Shows Strong Long-Term Survival Benefit in Melanoma

June 22, 2016

In this video we discuss 3-year results of the COMBI-d trial, which studied dabrafenib and trametinib in patients with unresectable or metastatic BRAF-mutated melanoma.